Mattias Mattsson
Överläkare vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Panagiotis Baliakas
- E-post:
- mattias.mattsson@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postadress:
- Rudbecklaboratoriet
751 85 UPPSALA
Publikationer
Senaste publikationer
Ingår i Leukemia, s. 675-683, 2025
- DOI för Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
- Ladda ner fulltext (pdf) av Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
Ingår i eJHaem, s. 998-1004, 2024
- DOI för Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
- Ladda ner fulltext (pdf) av Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
Ingår i Allergy. European Journal of Allergy and Clinical Immunology, s. 2470-2481, 2024
Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
Ingår i Journal of Molecular Diagnostics, s. 792-804, 2024
- DOI för Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
- Ladda ner fulltext (pdf) av Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
Ingår i Blood Advances, s. 2890-2900, 2024
- DOI för Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
- Ladda ner fulltext (pdf) av Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
Alla publikationer
Artiklar i tidskrift
Ingår i Leukemia, s. 675-683, 2025
- DOI för Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
- Ladda ner fulltext (pdf) av Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
Ingår i eJHaem, s. 998-1004, 2024
- DOI för Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
- Ladda ner fulltext (pdf) av Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
Ingår i Allergy. European Journal of Allergy and Clinical Immunology, s. 2470-2481, 2024
Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
Ingår i Journal of Molecular Diagnostics, s. 792-804, 2024
- DOI för Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
- Ladda ner fulltext (pdf) av Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
Ingår i Blood Advances, s. 2890-2900, 2024
- DOI för Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
- Ladda ner fulltext (pdf) av Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
Ingår i Blood Advances, s. 1713-1724, 2023
Ingår i Leukemia, s. 339-347, 2023
- DOI för Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
- Ladda ner fulltext (pdf) av Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
Ingår i Journal of Allergy and Clinical Immunology, s. 581-590, 2023
Ingår i British Journal of Haematology, s. 353-356, 2023
Ingår i The Lancet Oncology, s. 818-828, 2022
Ingår i American Journal of Hematology, 2022
Ingår i European Journal of Haematology, s. 369-378, 2022
- DOI för Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
- Ladda ner fulltext (pdf) av Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
Ingår i Leukemia, s. 516-524, 2022
Ingår i HemaSphere, 2022
- DOI för Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting
- Ladda ner fulltext (pdf) av Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
Ingår i Theranostics, s. 292-303, 2021
- DOI för Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
- Ladda ner fulltext (pdf) av Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
Ingår i HemaSphere, 2021
Ingår i Leukemia, s. 3444-3454, 2021
- DOI för COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
- Ladda ner fulltext (pdf) av COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Ingår i British Journal of Haematology, 2020
Ingår i BMJ Open, 2020
- DOI för Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
- Ladda ner fulltext (pdf) av Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
Ingår i American Journal of Hematology, 2020
5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome
Ingår i American Journal of Respiratory and Critical Care Medicine, s. 1051-1055, 2020
- DOI för 5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome
- Ladda ner fulltext (pdf) av 5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome
Ingår i Allergy. European Journal of Allergy and Clinical Immunology, s. 1927-1938, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
Ingår i Blood, s. 1859-1869, 2020
Ingår i Clinical Cancer Research, s. 1507-1515, 2020
Ingår i Leukemia, s. 1090-1101, 2020
Ingår i EBioMedicine, s. 150-158, 2019
- DOI för Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
- Ladda ner fulltext (pdf) av Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
Ingår i Haematologica, 2019
- DOI för Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
- Ladda ner fulltext (pdf) av Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Ingår i Haematologica, s. 797-805, 2019
Ingår i Haematologica, s. 360-369, 2019
- DOI för Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
- Ladda ner fulltext (pdf) av Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
Ingår i Haematologica, 2018
Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients
Ingår i European Journal of Clinical Microbiology and Infectious Diseases, s. 1673-1678, 2018
- DOI för Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients
- Ladda ner fulltext (pdf) av Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients
Ingår i Blood, 2018
Ingår i Haematologica, s. 714-714, 2017
Ingår i Haematologica, s. 121-122, 2017
Is FCR the treatment of choice for IGHV mutated CLL without poor FISH cytogenetics?
Ingår i Leukemia and Lymphoma, s. 170-171, 2017
Natural IgM antibodies in the immune defence against neoehrlichiosis
Ingår i Infectious Diseases, s. 809-816, 2017
Ingår i Epigenetics, s. 449-455, 2016
Ingår i Haematologica, s. 231-231, 2016
UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Ingår i Haematologica, 2016
Ingår i Haematologica, s. 1573-1580, 2016
Ingår i Haematologica, s. 426-426, 2016
Ingår i Blood, 2015
Ingår i Blood, 2015
Ingår i Haematologica, s. 52-52, 2015
Ingår i Stem Cells Translational Medicine, s. 1199-1213, 2015
Ingår i Blood, 2015
Ingår i Blood, 2015
First report from the Swedish CLL-registry: a nationwide registry with high coverage
Ingår i Leukemia and Lymphoma, s. 42-42, 2015
Clonal evolution patterns in high-risk chronic lymphocytic leukemia treated with ibrutinib
Artiklar, forskningsöversikt
Ingår i Journal of Allergy and Clinical Immunology, s. 81-87, 2019
Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?
Ingår i Journal of Internal Medicine, s. 347-357, 2016
Doktorsavhandlingar, sammanläggning
Kapitel i böcker, delar av antologi
BTK-inhibitors: Focus on Ibrutinib and similar Agents
Ingår i Resistance of targeted therapies excluding antibodies for lymphomas, Springer, 2018